Efpeglenatide and Heart and Kidney Outcomes in Type 2 Diabetes

Borderie, Gauthier; Schnebelen, Marie; Baynat, Louise

doi:10.1056/nejmc2115776

Cited by 3 publications

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Last, the point by Groothof et al on a creatinine-based estimated glomerular filtration rate has been previously discussed in correspondence. 2 It is notable that outcomes trials establishing SGLT2 inhibitors as drugs for kidney protection used creatinine to estimate glomerular filtration rate.…”

Section: In Responsementioning

confidence: 99%

Response by Lam and Gerstein to Letter Regarding Article, “Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial”

Lam

Gerstein

2022

Circulation

View full text Add to dashboard Cite

Section: In Responsementioning

confidence: 99%

Response by Lam and Gerstein to Letter Regarding Article, “Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial”

Lam

Gerstein

2022

Circulation

View full text Add to dashboard Cite

Muscle mass and estimates of renal function: a longitudinal cohort study

Groothof

Post

Polinder-Bos

et al. 2022

J cachexia sarcopenia muscle

View full text Add to dashboard Cite

Background Creatinine is the most widely used test to estimate the glomerular filtration rate (GFR), but muscle mass as key determinant of creatinine next to renal function may confound such estimates. We explored effects of 24-h height-indexed creatinine excretion rate (CER index) on GFR estimated with creatinine (eGFR Cr ), muscle mass-independent cystatin C (eGFR Cys ), and the combination of creatinine and cystatin C (eGFR Cr-Cys ) and predicted probabilities of discordant classification given age, sex, and CER index. Methods We included 8076 adults enrolled in the PREVEND study. Discordant classification was defined as not having eGFR Cr <60 mL/min per 1.73 m 2 when eGFR Cys was <60 mL/min/1.73 m 2 . Baseline effects of age and sex on CER index were quantified with linear models using generalized least squares. Baseline effects of CER index on eGFR were quantified with quantile regression and logistic regression. Effects of annual changes in CER index on trajectories of eGFR were quantified with linear mixed-effects models. Missing observations in covariates were multiply imputed. Results Mean (SD) CER index was 8.0 (1.7) and 6.1 (1.3) mmol/24 h per meter in male and female participants, respectively (P difference < 0.001). In male participants, baseline CER index increased until 45 years of age followed by a gradual decrease, whereas a gradual decrease across the entire range of age was observed in female participants. For a 70-year-old male participant with low muscle mass (CER index of 2 mmol/24 h per meter), predicted baseline eGFR Cr and eGFR Cys disagreed by 24.7 mL/min/1.73 m 2 (and 30.1 mL/min/1.73 m 2 when creatinine was not corrected for race). Percentages (95% CI) of discordant classification in male and female participants aged 60 years and older with low muscle mass were 18.5% (14.8-22.1%) and 15.2% (11.4-18.5%), respectively. For a 70-year-old male participant who lost muscle during follow-up, eGFR Cr and eGFR Cys disagreed by 1.5, 5.0, 8.5, and 12.0 mL/min/1.73 m 2 (and 6.7, 10.7, 13.5, and 15.9 mL/min/1.73 m 2 when creatinine was not corrected for race) at baseline, 5 years, 10 years, and 15 years of follow-up, respectively. Conclusions Low muscle mass may cause considerable overestimation of single measurements of eGFR Cr . Muscle wasting may cause spurious overestimation of repeatedly measured eGFR Cr . Implementing muscle mass-independent markers for estimating renal function, like cystatin C as superior alternative to creatinine, is crucial to accurately assess renal function in settings of low muscle mass or muscle wasting. This would also eliminate the negative consequences of current race-based approaches.

show abstract

The Effect of GLP-1 Receptor Agonists on Postprandial Lipaemia

Novodvorský

Haluzı́k

2022

Curr Atheroscler Rep

View full text Add to dashboard Cite

Efpeglenatide and Heart and Kidney Outcomes in Type 2 Diabetes

Cited by 3 publications

References 13 publications

Response by Lam and Gerstein to Letter Regarding Article, “Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial”

Response by Lam and Gerstein to Letter Regarding Article, “Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial”

Muscle mass and estimates of renal function: a longitudinal cohort study

The Effect of GLP-1 Receptor Agonists on Postprandial Lipaemia

Contact Info

Product

Resources

About